Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XcelerateXCRT -2.36% FCF Margin % is 34.77% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Xcelerate ranks better than 90.09% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Xcelerate's Free Cash Flow for the
three
months ended in Sep. 2025 was $0.19 Mil. Xcelerate's Revenue for the
three
months ended in Sep. 2025 was $0.53 Mil. Therefore, Xcelerate's FCF Margin % for the quarter that ended in Sep. 2025 was 34.77%.
The historical data trend for Xcelerate's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Xcelerate's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xcelerate FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Xcelerate's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Xcelerate's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xcelerate (XCRT) has a FCF Margin % of 34.77% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Xcelerate and its competitors. According to the industry distribution chart, Xcelerate ranks #66 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 9.9%.
Is Xcelerate's FCF Margin % too high?
Xcelerate's current FCF Margin % is 34.77%. The Healthcare Providers & Services industry median FCF Margin % is 3.11. Xcelerate's value of 34.77% is 1018% above this industry median. Based on the distribution chart, Xcelerate ranks #66 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Xcelerate's FCF Margin % compare to RHEP and NIVF?
According to the Healthcare Providers & Services industry distribution chart, Xcelerate ranks #66 out of 666 companies for FCF Margin %. This places Xcelerate in the top 10% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.11. Xcelerate's value of 34.77% is 1018% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.11, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xcelerate's current FCF Margin % of 34.77% is 1018% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Xcelerate and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xcelerate's current FCF Margin % is 34.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xcelerate stock overvalued right now?
Xcelerate (XCRT) has a current FCF Margin % of 34.77%. The current FCF Margin % is 34.77% and 1018% above the Healthcare Providers & Services industry median of 3.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Xcelerate (XCRT), the current FCF Margin % is 34.77% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xcelerate Inc is a healthcare services and products company engaged in three separate but related businesses within the medical, health, and wellness sectors. It is focused on the development of medical technology and the provision of virtual health services to help patients in developing countries meet their medical needs by extending the reach of physicians through technology. The company is also involved in the formulation, packaging, and marketing of consumer health and beauty, clinically tested skin and hair care products, and owns and licenses the rights to various forms of medical equipment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCRT has been successfully added to your 
